S Serdengeçti, E Büyükünal, N Molinas, F H Demirelli, N Berkarda, H Eyüboğlu, U Derman, B Berkarda
{"title":"非小细胞肺癌患者的总体生存结果:单独化疗与联合免疫调节化疗。","authors":"S Serdengeçti, E Büyükünal, N Molinas, F H Demirelli, N Berkarda, H Eyüboğlu, U Derman, B Berkarda","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The effect on long-term survival of immunomodulation adjuvant to various cytotoxic chemotherapy regimens in non-small cell lung cancer (NSCLC) was evaluated in 669 patients followed up between 1974 and 1987. Four hundred seventeen patients were treated only by cytotoxic chemotherapy and served as controls. Two hundred fifty-two patients received warfarin (W), levamisole (L) and tranexamic acid (T) for adjuvant immunomodulation. These drugs, especially when given in combination (W + L + T), led to a significant (p less than 0.05) enhancement of survival in patients with advanced NSCLC, independent of the cytotoxic regimen used.</p>","PeriodicalId":9733,"journal":{"name":"Chemioterapia : international journal of the Mediterranean Society of Chemotherapy","volume":"7 2","pages":"122-6"},"PeriodicalIF":0.0000,"publicationDate":"1988-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Overall survival results of non-small cell lung cancer patients: chemotherapy alone versus chemotherapy with combined immunomodulation.\",\"authors\":\"S Serdengeçti, E Büyükünal, N Molinas, F H Demirelli, N Berkarda, H Eyüboğlu, U Derman, B Berkarda\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The effect on long-term survival of immunomodulation adjuvant to various cytotoxic chemotherapy regimens in non-small cell lung cancer (NSCLC) was evaluated in 669 patients followed up between 1974 and 1987. Four hundred seventeen patients were treated only by cytotoxic chemotherapy and served as controls. Two hundred fifty-two patients received warfarin (W), levamisole (L) and tranexamic acid (T) for adjuvant immunomodulation. These drugs, especially when given in combination (W + L + T), led to a significant (p less than 0.05) enhancement of survival in patients with advanced NSCLC, independent of the cytotoxic regimen used.</p>\",\"PeriodicalId\":9733,\"journal\":{\"name\":\"Chemioterapia : international journal of the Mediterranean Society of Chemotherapy\",\"volume\":\"7 2\",\"pages\":\"122-6\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1988-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Chemioterapia : international journal of the Mediterranean Society of Chemotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chemioterapia : international journal of the Mediterranean Society of Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
本文对1974 ~ 1987年随访的669例非小细胞肺癌(NSCLC)患者进行了免疫调节佐剂对各种细胞毒性化疗方案的长期生存影响的评价。417名患者仅接受细胞毒性化疗，并作为对照。252例患者接受华法林(W)、左旋咪唑(L)和氨甲环酸(T)辅助免疫调节。这些药物，特别是当联合使用(W + L + T)时，导致晚期非小细胞肺癌患者的生存率显著提高(p < 0.05)，而不依赖于所使用的细胞毒性方案。
Overall survival results of non-small cell lung cancer patients: chemotherapy alone versus chemotherapy with combined immunomodulation.
The effect on long-term survival of immunomodulation adjuvant to various cytotoxic chemotherapy regimens in non-small cell lung cancer (NSCLC) was evaluated in 669 patients followed up between 1974 and 1987. Four hundred seventeen patients were treated only by cytotoxic chemotherapy and served as controls. Two hundred fifty-two patients received warfarin (W), levamisole (L) and tranexamic acid (T) for adjuvant immunomodulation. These drugs, especially when given in combination (W + L + T), led to a significant (p less than 0.05) enhancement of survival in patients with advanced NSCLC, independent of the cytotoxic regimen used.
分享
京公网安备 11010802042870号
京ICP备2023020795号-1
求助内容：
应助结果提醒方式：
扫码关注我们
